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Elsevier Taiwan LLC. Open access under CSummary Background: The study was conducted to reveal the most appropriate empiric an-
tibiotics for the treatment of community-acquired biliary tract infections (CA-BTI) at a regional
hospital in Taiwan.
Methods: The study was performed between October 1, 2010 and October 31, 2012. All posi-
tive bile culture results of presumptive community-acquired origins were collected. The asso-
ciated etiologic microorganisms and their antimicrobial susceptibilities were analyzed. The
appropriateness of empiric therapy (defined as the effectiveness of the antibiotics against
the etiologic agents) and the subsequent treatment response were examined through the re-
view of medical records.
Results: A total of 115 patients (cholecystitis, 83 cases, 72.2%; cholangitis, 32 cases, 27.8%)
and 189 isolates (136 Gram-negative bacilli, 37 Gram-positive cocci, and 16 anaerobes) were
analyzed. The most frequent pathogens were Escherichia coli (n Z 69, 36.5%), Klebsiella
spp. (nZ 37, 19.6%), enterococci (nZ 29, 15.3%), and Bacteroides spp. (nZ 11, 5.8%). Peni-
cillin resistance (5.4%) was low in Gram-positive cocci, whereas higher resistance (>20%) to ce-
fazolin, cefuroxime, and ampicillinesulbactam was found in Gram-negative bacilli. Anaerobes
also demonstrated high resistance to clindamycin (37.5%) but less to metronidazole (12.5%).
Appropriate empiric therapy was found in 92 (80%) cases, and among them, 83 (90.2%) were
treated successfully. The treatment success rate (69.6%) was significantly lower among the re-
maining 23 cases with inappropriate empiric therapy (16 of 23 vs. 83 of 92, p < 0.05). A high
treatment success rate (97.2%) was observed among cases empirically treated with ceftriaxone
plus metronidazole.
Conclusion: The combination of ceftriaxone plus metronidazole appears to be the most appro-
priate empiric antibiotics for the treatment of CA-BTI at this hospital. Because different hos-
pitals may encounter microorganisms of different antimicrobial susceptibilities, similarof Infection Control, Tainan Municipal Hospital, No. 670 Chung-Te Road, Tainan 701, Taiwan.
om.tw (C.-L. Chang).
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Antibiotics for biliary tract infections 55approaches may be followed by other hospitals where appropriate empiric therapy has not yet
been established for the treatment of CA-BTI.
Copyright ª 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy So-
ciety of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Introduction
Biliary tract infections (BTI), including cholangitis and
cholecystitis, usually result from biliary tract obstruction.
From the standpoint of medical treatment, the most
important approaches may include supportive treatment,
administration of antibiotics, and exploring primary sour-
ces, such as biliary drainage, operation for removal of
biliary tract stones, and cholecystectomy. Among these
approaches, primary source control may be the most
important. Early and instantaneous primary source control
has been shown to be vital for the treatment of severe in-
fections and may help to decrease mortality [1,2].
Furthermore, if biliary obstruction is present, primary
source control may facilitate the penetration of antibiotics
through the biliary tract, leading to a better bactericidal
effect [3,4].
In addition to primary source control, administration of
antibiotics is also crucial for the treatment of BTI. The
etiologic agents of BTI usually originate from endogenous
flora of the gastrointestinal tract, with Escherichia coli,
Klebsiella spp., enterococci, and Bacteroides spp. being
the most frequent. Hence, antibiotics that are effective
against these organisms are usually used empirically to
treat BTI [5e10]. However, inappropriate empiric antibi-
otics may also incur fatal outcomes [11,12].
Because the causative agents of BTI and the associated
antimicrobial susceptibility patterns may vary in different
hospitals [7e10], the establishment of appropriate thera-
peutic regimens for the individual hospitals appears
necessary. The present study was therefore conducted to
reveal the most appropriate empiric antibiotics for the
treatment of community-acquired BTI (CA-BTI) at a 600-bed
regional hospital in southern Taiwan. The bacteriology and
the associated antimicrobial susceptibility patterns related
to the CA-BTI were analyzed. To achieve the best thera-
peutic effects, the penetration ability of the antibiotics
through the biliary tract was also considered [13,14].Methods
Between October 1, 2010 and October 31, 2012, all positive
results of bile cultures of presumptive community-acquired
origins at a regional hospital in southern Taiwan were
collected. Both aerobic and anaerobic cultures were
routinely performed for bile specimens at this hospital and
were included in the analysis. To prevent from the inclusion
of some hospital-acquired pathogens, bile specimens that
were submitted more than 3 days after hospitalization as
well as those from patients readmitted within 6 months
were excluded. In addition, medical records of the patients
were reviewed, and information regarding age, sex,diagnosis, invasive procedures to collect the bile speci-
mens, empiric antibiotics, and treatment response were
collected for further analysis.
The appropriateness of empiric antibiotics was evalu-
ated according to the antimicrobial susceptibility testing
results. The empiric antibiotics were categorized as
appropriate if the etiologic microorganisms demonstrated
susceptibility to the antibiotics used. By contrast, if any of
the antibiotics used was categorized as resistant in the
associated antimicrobial susceptibility testing, the empiric
antibiotics would be deemed as inappropriate. Successful
treatment was defined as the improvement of the following
three clinical conditions: fever subsided gradually, the pa-
tient’s general condition improved, and laboratory data
became normal. If any of the conditions was not achieved,
the case would be defined as treatment failure.
Standard laboratory methods were used to perform the
bile culture and isolation and identification of microor-
ganisms. Disk diffusion and limited agar dilution methods
were used to determine the antimicrobial susceptibility for
aerobic and anaerobic bacteria, respectively. The antibi-
otics tested for Gram-negative bacilli (GNBs) were as fol-
lows: cefazolin (30 mg), cefuroxime (30 mg), ceftriaxone
(30 mg), ceftazidime (30 mg), gentamicin (10 mg), amikacin
(30 mg), levofloxacin (5 mg), and ampicillinesulbactam (10/
10 mg). For Gram-positive cocci (GPCs), penicillin (10 units)
and vancomycin (30 mg) were tested. All these antimicro-
bial disks were purchased from Becton, Dickinson and
Company (Franklin Lakes, NJ, USA). Clindamycin (2 mg/
4 mg) and metronidazole (8 mg/16 mg) were tested for an-
aerobes. Both disks were purchased from Creative Media
Products, Ltd. (New Taipei City, Taiwan).
Results of the antimicrobial susceptibility testing were
interpreted according to the current standards recom-
mended by the Clinical and Laboratory Standards Institute.
All intermediate results were regarded as resistant in this
study.
The Chi-square test was used for the statistical analysis.
A difference was considered statistically significant when
the p value was <0.05.
Results
A total of 115 patients and 189 isolates were collected in
the present study. Among the 115 patients, 66 (57.4%) were
male and 29 (25.2%) were aged <60 years. The majority
(83, 72.2%) of the patients had cholecystitis, and the
remaining (32, 27.8%) were cholangitis. In the 83 patients
with cholecystitis, bile specimens were obtained either
from percutaneous gallbladder drainage (54, 65.1%) or
through operation (29, 34.9%). In the 32 patients with
cholangitis, bile specimens were withdrawn by one of the
following procedures: percutaneous transhepatic drainage
56 K.-K. Chang et al.(14, 43.8%); percutaneous gallbladder drainage (9, 28.1%);
operation (7, 21.8%); and endoscopic nasobiliary drainage
(2, 6.3%).
The 189 isolates comprised 136 (72.0%) GNBs, 37 (19.5%)
GPCs, and 16 (8.5%) anaerobes. Polymicrobial infection,
i.e., two or more bacterial species were simultaneously
isolated from the same specimens, was found in 45 (39.1%)
patients, including 15 (13%) mixed infection with anaer-
obes. Distribution of the 189 isolates among various bac-
terial genuses/species and the associated rates of
resistance to various antimicrobial agents are listed in
Table 1. The most frequent organisms were E. coli (69,
36.5%) and Klebsiella spp. (37, 19.6%). Some minor GNBs
were also found, including three each of Pseudomonas
aeruginosa and Proteus mirabilis, one each of Acineto-
bacter baumannii, Morganella morgannii, Serratia mar-
cescens, Hafnia spp., and one unidentified glucose-
nonfermenting GNB. None of the 136 GNBs was resistant
to amikacin. Resistance to ceftazidime and gentamicin was
also low (4.4%, respectively). Although the overall resis-
tance to ceftriaxone (8.0%) and levofloxacin (13.2%) was
not high, a wide range of resistance rates from 0% (for both
antibiotics) in Klebsiella spp. to 50.0% (for levofloxacin) in
Enterobacter spp. was also noted. High resistance rates
(>20%) were observed for the remaining three antibiotics
(cefazolin, cefuroxime, and ampicillinesulbactam), with
full resistance (100%) demonstrated by Enterobacter spp.
(to all 3 agents) and Aeromonas spp. (to cefazolin and
ampicillinesulbactam).
Most of the GPCs were enterococci (29, 15.3%), and the
remaining were streptococci (8, 4.2%). All the GPCs were
susceptible to both penicillin and vancomycin, except that
two penicillin-resistant enterococci were also noted. The
anaerobes identified were Bacteroides spp. (n Z 11),
Clostridium spp. (nZ 4), and Prevotella spp. (nZ 1). They
showed high resistance to clindamycin (37.5%) but less to
metronidazole (12.5%; Table 1).
Empiric antibiotics and treatment responses of the pa-
tients are shown in Table 2. The most frequent empiric
antibiotics were ceftriaxone plus metronidazole (36,
31.3%) and cefuroxime plus metronidazole (28, 24.3%).Table 1 Distribution of the 189 isolates among various bacteri
various antimicrobial agents.
Bacteria No. of
isolates
Antimicrobial resistance (%)
CZ CXM CRO CAZ
Escherichia coli 69 34.8 8.7 4.3 4.3
Klebsiella spp. 37 37.8 2.7 0.0 0.0
Enterobacter spp. 8 100.0 100.0 12.5 12.
Citrobacter spp. 6 100.0 83.3 16.7 0.0
Aeromonas spp. 5 100.0 20.0 20.0 0.0
Other GNBs 11 90.9 63.6 45.5 18.
Total GNBs 136 49.3 20.6 8.0 4.4
Enterococci 29 d d d d
Streptococci 8 d d d d
Anaerobes 16 d d d d
All Gram-negative bacilli were susceptible to amikacin.
CAZ Z ceftazidime; CLIN Z clindamycin; CRO Z ceftriaxone; CXM Z
negative bacilli; LVX Z levofloxacin; MET Z metronidazole; PCN Z
d Z not tested.Most (92, 80%) of the patients received appropriate
empiric antibiotics, whereas the remaining 23 (20%) were
deemed inappropriate. The majority (83, 90.2%) of the
patients in the appropriate empiric antibiotics group
demonstrated successful treatment responses. Ceftriax-
one plus metronidazole, although the most frequent
antibiotic combination used, also appeared to be highly
effective. The only failure was found in the inappropriate
treatment group, with one of the etiologic agents, E. coli,
being resistant to the ceftriaxone used. Thus, if only the
appropriate empiric antibiotics were considered, this
antibiotic combination actually reached a full success
treatment rate of 100%. Some other antibiotics, such as
cefazolin, flomoxef, and doripenem also demonstrated a
full success rate of 100%, although these were only used in
five or fewer patients. Among the nine patients whose
treatment failed, six (3 cases of cefuroxime plus metro-
nidazole, 1 case of cefmetazole, 1 case of cefazolin plus
metronidazole, and 1 case of ceftazidime plus metroni-
dazole) were subsequently treated successfully with cef-
triaxone plus metronidazole. Another case of treatment
failure with levofloxacin also demonstrated successful re-
sponses when ceftriaxone was used subsequently. Three
patients died despite all receiving appropriate empiric
antibiotics. The cause of death in the patient treated with
ceftazidime plus metronidazole was other underlying dis-
eases rather than uncontrolled infections, whereas the
remaining two were due to septic shock complicated with
multiple organ failure.
Among the 23 patients receiving inappropriate empiric
antibiotics, 16 (69.6%) were still treated successfully. These
empiric antibiotics were ceftriaxone plus metronidazole
(n Z 3), ceftriaxone (n Z 1), cefuroxime plus metronida-
zole (n Z 4), cefuroxime (n Z 1), cefmetazole (n Z 2),
cefazolin plus metronidazole (n Z 2), cefazolin (n Z 1),
moxifloxacin (n Z 1), and flomoxef (n Z 1). Of the seven
patients with treatment failure, three received cefmeta-
zole, cefuroxime plus metronidazole, and cefuroxime,
respectively, and were subsequently treated successfully
with ceftriaxone plus metronidazole, the appropriate
empiric antibiotics in two of the patients.al genuses/species and the associated rates of resistance to
GM LVX SAM PCN VAN CLIN MET
5.8 15.9 23.2 d d d d
0.0 0.0 10.8 d d d d
5 0.0 50.0 100.0 d d d d
0.0 16.7 66.7 d d d d
0.0 20.0 100.0 d d d d
2 18.2 18.2 63.6 d d d d
4.4 13.2 33.8 d d d d
d d d 6.9 0.0 d d
d d d 0.0 0.0 d d
d d d d d 37.5 12.5
cefuroxime; CZ Z cefazolin; GM Z gentamicin; GNBs Z Gram-
penicillin; SAM Z ampicillinesulbactam; VAN Z vancomycin;
Table 2 Empiric antibiotics administered and the corresponding treatment responses among the 115 patients studied.
Empiric antibiotics No. of cases Evaluation of appropriateness Treatment response Mortality
Appropriate Inappropriate Success Failure
CXM þ M 28 22 (78.6) 6 (21.4) 23 (82.1) 5 (17.9) 0 (0.0)
CXM 4 2 (50.0) 2 (50.0) 3 (75.0) 1 (25.0) 0 (0.0)
CRO þ M 36 32 (88.9) 4 (11.1) 35 (97.2) 1 (2.8) 0 (0.0)
CRO 5 4 (80.0) 1 (20.0) 4 (80.0) 1 (20.0) 0 (0.0)
CZ þ M 8 5 (62.5) 3 (37.5) 6 (75.0) 2 (25.0) 0 (0.0)
CZ 5 4 (80.0) 1 (20.0) 5 (100.0) 0 (0.0) 0 (0.0)
CAZ þ M 2 2 (100.0) 0 (0.0) 1 (50.0) 1 (50.0) 1 (50.0)
LEV 4 4 (100.0) 0 (0.0) 2 (50.0) 2 (50.0) 1 (50.0)
MOX 6 4 (66.7) 2 (33.3) 5 (83.3) 1 (16.7) 0 (0.0)
CMZ 7 4 (57.1) 3 (42.9) 6 (85.7) 1 (14.3) 0 (0.0)
FLO 4 3 (75.0) 1 (25.0) 4 (100.0) 0 (0.0) 0 (0.0)
DOR 5 5 (100.0) 0 (0.0) 5 (100.0) 0 (0.0) 0 (0.0)
IMP 1 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
Total 115 92 (80.0) 23 (20.0) 99 (86.1) 16 (13.9) 3 (2.6)
Appropriate empiric antibiotics (n Z 92) 83 (90.2) 9 (9.8) 3 (3.3)
Inappropriate empiric antibiotics (n Z 23) 16 (69.6) 7 (30.4) 0 (0.0)
Data are presented as n (%).
CAZZ ceftazidime; CMZZ cefmetazole; CROZ ceftriaxone; CXMZ cefuroxime; CZZ cefazolin; DORZ doripenem; FLOZ flomoxef;
IMP Z imipenem; LEV Z levofloxacin; M Z metronidazole; MOX Z moxifloxacin.
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enterococci, 27 received empiric antibiotics without anti-
enterococcal activities, but 26 (96.3%) demonstrated suc-
cessful responses. In the only case of treatment failure, the
bile culture also grew E. coli, which was resistant to the
empiric antibiotics used. Overall, the treatment success
rate of appropriate empiric antibiotics was significantly
higher than that of inappropriate empiric antibiotics (83 of
92 vs. 16 of 23, p < 0.05, c2 test).Table 3 The antibiotics usually used to treat biliary tract
infections and their biliary penetration ability (indicated as
the ratio of bile to serum concentrations) [16e19].
Good penetration efficiency
(1)
Low penetration efficiency
(<1)
Antibiotics Bile/serum Antibiotics Bile/serum
Tazocin 60 Cefotaxime 0.75
Tigecycline 38 Meropenem 0.75
Augmentin 30 Ceftazidime 0.5
Ciprofloxacin 30 Vancomycin 0.5
Unasyn 9 Amikacin 0.3
Ceftriaxone 5 Gentamicin 0.3
Levofloxacin 5 Cefepime 0.1
Penicillin G 5 Imipenem 0.01
Cefazolin 3
Clindamycin 3
Doripenem 1.17
Cefuroxime 1
Metronidazole 1
Augmentin Z amoxicillineclavulanate; Bile/serum Z bile
concentration/serum concentration; Tazocin Z piper-
acillinetazobactam; Unasyn Z ampicillinesulbactam.Discussion
From the standpoint of medical treatment, the selection of
empiric antibiotics has to consider two important factors.
First, >80% of the suspected etiologic microorganisms
should be susceptible to the antibiotics, and, for patients
with septic shock, the susceptibility rates should even
reach 100% to obtain favorable treatment responses [15].
Second, the antibiotics should yield sufficient concentra-
tions at the sites of infection to produce the expected
antimicrobial effect [13,14]. Hence, both the susceptibility
rates and the ability of biliary penetration should be
considered when selecting empiric antibiotics for the
treatment of BTI. The antibiotics usually used to treat BTI
and their biliary penetration ability (indicated as the ratio
of bile to serum concentrations) are listed in Table 3
[16e19]. According to the criteria mentioned above, only
those with a satisfactory ratio (1) of bile to serum con-
centrations (Table 3) could be the candidate of empiric
antibiotics for BTI. Appropriate empiric antibiotics should
further consider the local antimicrobial susceptibility pat-
terns of the usual etiologic agents for BTI. Only those with
resistance rates of <20% should be used as empiric antibi-
otics to ensure a favorable outcome.
Previous reports have indicated that the common etio-
logic agents for BTI usually include E. coli, Klebsiella spp.,
enterococci, and Bacteroides spp. [5e10]. Similar results
were also noted in the present study. Furthermore,
although anaerobes were identified from only 15 (13%) pa-
tients, they were usually associated with polymicrobial in-
fections, especially with GNBs. Hence, the empiric
antibiotics used should be effective against both groups of
microorganisms, regardless whether anaerobes are isolated
[20]. In the present study, metronidazole was found to be
the preferred option with a much lower resistance rate
(12.5%) compared to that (37.5%) of clindamycin.
58 K.-K. Chang et al.Whether to treat enterococci remains controversial
when the organisms are isolated from bile specimens. In
most conditions, enterococci do not need antimicrobial
treatment [21,22]. In the present study, most of the pa-
tients with positive bile cultures for enterococci did not
receive antibiotics with known antienterococcal activity.
However, only one treatment failure was subsequently
found, probably due to the antimicrobial resistance of the
other organism that concomitantly caused the BTI. It ap-
pears that antienterococcal activity is not important when
empiric antibiotics are to be selected for treating CA-BTI.
Cefazolin (to treat GNBs and streptococci) plus metro-
nidazole (to treat anaerobes) has long been regarded as the
first-line empiric antibiotic combination for CA-BTI. How-
ever, our data did not support this recommendation due to
the high resistance rate observed. Even cefuroxime and
ampicillinesulbactam were inappropriate with resistance
rates of both being >20%. Therefore, third-generation
cephalosporins (such as ceftriaxone and ceftazidime) and
fluoroquinolones (such as levofloxacin and ciprofloxacin)
may serve as the preferred options due to the lower resis-
tance rates (<20%).
According to the above analysis, metronidazole plus
ceftriaxone or levofloxacin may be the most appropriate
empiric antibiotics to treat CA-BTI. When the resistance
rates and medical cost are further considered, ceftriaxone
appears to be superior to levofloxacin. Hence, we suggest
that ceftriaxone plus metronidazole is the most appropriate
empiric antibiotic combination to treat CA-BTI at this hos-
pital. The suggestion also could be supported by the high
treatment success rate (97.2%) of ceftriaxone plus metro-
nidazole observed in the present study. Moreover, some of
the treatment failures with other antibiotics were subse-
quently treated successfully with ceftriaxone plus metro-
nidazole. However, if antibiotics are necessary for
outpatient treatment, oral levofloxacin (or ciprofloxacin)
plus metronidazole may still serve as the appropriate
alternative antibiotics.
In this study, 26 (22.6%) patients also developed
bacteremia. Hence, antibiotics with lower serum concen-
trations cannot be used as empiric antibiotics to treat BTI.
For example, tigecycline is effective against GPCs, GNBs,
and anaerobes. It is also recommended as an empiric
antibiotic for treating BTI due to the low resistance rates
and high biliary penetration abilities [23]. However, none of
the patients was administered with the antibiotic in the
present study. Moreover, we disagree with this recom-
mendation because tigecycline was known to be associated
with lower serum concentrations and thus may result in
treatment failure if bacteremia is simultaneously present
[24e26].
Biliary drainage and administration of appropriate anti-
biotics are two most important approaches to treat BTI,
especially for cholangitis. More precisely, biliary drainage is
even more important than the administration of appro-
priate antibiotics. Biliary drainage is a method of primary
source control and can allow antibiotics to penetrate
effectively into the biliary tract where the infection occurs.
However, administration of appropriate empiric antibiotics
is also important. Based on results from the present study,
we recommend that ceftriaxone plus metronidazole may be
the appropriate empiric antibiotic combination to treat CA-BTI at this hospital. In addition, we also suggest that every
hospital should have its own guideline in this regard
because different etiologic organisms with various antimi-
crobial susceptibility patterns may be present [5], espe-
cially in areas where multidrug-resistant infections have
been increasing.Conflicts of interest
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